31.90SEK+10.76%Mkt Cap: 46.98M SEKP/E: —Last update: 2026-05-13
Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a powerful tool for high precision cell biology that us…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B4.31
P/S3.09
EV/EBITDA-5.43
EV/Revenue2.87
EPS (TTM)-6.06
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-26.86%
FCF Margin-82.92%
Operating CF-4.94M SEK
CapEx (TTM)8.67M SEK
Net Debt/EBITDA0.28
Net Debt-2.26M SEK
Technical
SMA 5014.98 (+113.0%)
SMA 20012.73 (+150.5%)
Beta1.47
S&P 52W Chg24.23%
Avg Vol (30d)15.62K
Avg Vol (10d)51.39K
Technical Indicators
RSI (14)73.8
MACD4.1923
MACD Signal2.4221
MACD Hist.+1.7702
BB Upper31.27 SEK
BB Middle17.77 SEK
BB Lower4.269 SEK
BB Width151.95%
ATR (14)3.827 SEK
Vol Ratio (20d)1.36x
52W Range
7.45069% of range43.10
52W High43.10 SEK
52W Low7.450 SEK
Profitability
Gross Margin218.79%
EBITDA Margin-52.73%
Profit Margin-138.82%
Oper. Margin-1.58%
ROE-76.43%
ROA-45.10%
Revenue Growth50.40%
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio1.00
Quick Ratio0.59
Book Value/Sh7.935 SEK
Cash/Share1.647 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:350
Split DateMar 26, 2025
Ownership
Shares Out.1.37M
Float1.23M
Insiders24.73%
Institutions3.50%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap46.98M SEK
Enterprise Value43.62M SEK
Revenue (TTM)15.22M SEK
Gross Profit13.13M SEK
Net Income (TTM)-8.33M SEK
Revenue/Share11.08 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees11
Last Price31.90 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0010831321